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e166Introduction: Female sexual arousal disorder is a pathophysiologic state characterized clinically by persistent or
recurrent inability to attain or maintain an adequate lubrication-swelling response of sexual excitement until
completion of sexual activity. Prior clinical experience with alprostadil products for men with erectile dysfunction
supports its use in women with female sexual arousal disorder.
Aim: To compare the effect of topical alprostadil with over-the-counter (OTC) lubricant on female genital
arousal in the absence of visual sexual stimuli.
Methods: Healthy premenopausal women without sexual dysfunction were recruited from the community to
participate in the study. Of 17 women who consented, 10 were enrolled and completed the trial. The mean age
of subjects was 32 years (range ¼ 27e43). Study drug or placebo was applied topically to the genitals.
Continuous temperature monitoring was performed. Participants completed questionnaires assessing genital
sensation, effect, intensity, and duration.
Main Outcome Measures: Change in temperature from baseline in vestibule, clitoris and vulva.
Results: In all 10 subjects, topical alprostadil induced a statistically signiﬁcant increase in temperature of the
vestibule, clitoris, and vulva compared with the OTC lubricant. The most rapid difference in genital temperature
between placebo and alprostadil was seen on the vulva, which demonstrated a signiﬁcant difference at approx-
imately 9 minutes. There was a signiﬁcant difference in temperature seen for the vestibule and clitoris at 11 and
19 minutes, respectively. Sixty percent of women reported being aware or conscious of genital sensations with
topical alprostadil, but not with OTC lubricant. Discordance was noted in 30% of subjects who reported being
aware or conscious of genital sensations with the two treatments and 10% who reported not being aware or
conscious of genital sensations with either treatment.
Conclusion: Topical alprostadil administered to healthy premenopausal women induced statistically signiﬁcant,
sustained increases in genital temperatures of the vestibule, clitoris, and vulva within 20 minutes compared with
OTC lubricant.
Sex Med 2016;4:e166ee175. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Female sexual dysfunction (FSD) is a multidisciplinary,
biopsychosocial concern that can present with many distressing
symptoms such as low sexual desire, decreased peripheral and/or
central sexual arousal, orgasm dysfunction, and/or pain or
discomfort during sexual activity.1,2 The prevalence of overall
FSD, independent of associated distress, has been estimated to be
43% of women.3 The prevalence of FSD surpasses that of male
sexual dysfunction.4,5 Symptoms of FSD, when associated with
distress, have been shown to negatively affect quality of life.3Sex Med 2016;4:e166ee175
Peripheral Genital Arousal Assessed by Thermography e167In women, physiologic sexual stimulation results in pelvic
nerve-mediated genital smooth muscle relaxation and subsequent
increases in hypogastric-pudendal arterial blood inﬂow. Initiation
and maintenance of female sexual arousal consists, in part, of
clitoral, vulvar, vestibular, and vaginal vasodilation, genital
engorgement, and enhanced genital lubrication.6,7 Female sexual
arousal disorder (FSAD) is a pathophysiologic state characterized
clinically by persistent or recurrent inability to attain or maintain
an adequate lubrication-swelling response of sexual excitement
until completion of sexual activity.8 The prevalence of women
with arousal complaints accompanied by distress is estimated to
be 3% to 8% across all age groups.1,9 Shifren et al10 reported that
the prevalence of distressing FSAD was 5.4%. Epidemiologic
studies have shown that comorbidities of metabolic syndrome,
such as obesity, diabetes, cardiovascular disease, and hyperten-
sion, can contribute to female genital arousal disorder.11e17 Such
comorbidities are associated, in part, with atherosclerotic lesions
in the hypogastric-pudendal arterial bed that negatively restrict
blood inﬂow increases to the peripheral genitalia during sexual
arousal. Although the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition has suggested that FSAD should be
linked to hypoactive sexual desire disorder (HSDD) in the entity
“female sexual interest-arousal disorder,” this remains contro-
versial. The International Society for the Study of Women’s
Sexual Health and other societies have determined that the use of
FSAD and HSDD as separate conditions should continue in
clinical and research settings. The present research was performed
in healthy women without sexual dysfunctions.
Prostaglandin E1 (PGE1) naturally occurs in humans. PGE1 is
a vasodilator that produces an increase in intracellular cyclic
adenosine monophosphate and activation of protein kinase A.
PGE1, unlike phosphodiesterase type 5 inhibitors (PDE5Is),
increases blood ﬂow without the need for sexual arousal.
Increased protein kinase A activity has been shown to induce
genital smooth muscle relaxation that in women can result in
vulvovaginal vasodilation and enhanced genital lubrication,
which are components of genital arousal.6,7 Alprostadil is a
vasoactive, synthetic form of PGE1 that has been approved
worldwide for several intracavernosal and intraurethral products
to treat erectile dysfunction.18e21 Prior clinical experience with
alprostadil products for men with erectile dysfunction supports
its use in women with FSAD.22e25 Several studies have exam-
ined the use of alprostadil in the treatment of FSAD, but effects
on genital arousal from these previous investigations have largely
been measured in a sexual context.22e25 Becher et al26 studied
topical alprostadil on the clitoris alone using duplex Doppler
sonography, but heretofore no one has studied the genital
changes from application of alprostadil to the external genitalia
compared with placebo. It is unknown whether topical alpros-
tadil increases genital temperature (blood ﬂow) and arousal
without visual stimulation.
The objective of this proof-of-principle study was to evaluate
the effect of a topical alprostadil cream (Femprox, ApricusSex Med 2016;4:e166ee175Biosciences, Inc, San Diego, CA, USA) 1,000 mg on the external
genitalia of sexually healthy women in the absence of sexual
stimulus compared with an over-the-counter (OTC) marketed
lubricant using forward-looking infrared (FLIR) thermography as
a measurement of genital blood ﬂow. The use of thermography
as a method of measuring female sexual arousal has been well
validated.27e32 This was an investigator-initiated pilot study to
determine whether a larger study in women with FSAD might be
feasible. This novel study design was more rigorous than previous
studies in its ability to assess genital blood ﬂow changes in
women using alprostadil. This single-blinded, placebo-controlled
clinical trial used a non-invasive tool for measuring blood ﬂow
changes and timing of those changes without the confounding
inﬂuence of sexual arousal in an ofﬁce setting.METHODS
Study Design
A prospective, randomized, single-center, single-blinded, cross-
over, proof-of-principle study was performed under independent
review board approval. The study involved two counterbalanced
crossover visits, each consisting of thermographic assessment of
vestibular, clitoral region, and vulvar responses to non-sexual
stimuli (ie, travel ﬁlm) and completion of several self-report
questionnaires. Alprostadil and placebo were randomized at the
start of the trial and applied by an unblinded clinician who had no
other involvement in the study, so that all other study procedures
were performed and results were assessed in blinded fashion. The
two visits of study drug application were scheduled with a washout
(minimum ¼ 1 day, maximum ¼ 7 days) between visits.Subjects
Healthy premenopausal women without sexual dysfunction
were recruited from the community to participate in the study.
The intention of the study was to enroll up to 15 subjects to
obtain 10. Of 17 who consented, 10 were enrolled and
completed the trial. The mean age of the subjects was 32 years
(range ¼ 27e43). Six subjects were Caucasian (ﬁve of whom
identiﬁed as Hispanic), two were Paciﬁc Islanders, one was
Black, and 1 was East Asian. Only heterosexual women were
included in the study.
Subjects had to be in good general health as determined by
medical history, physical examination, and laboratory testing,
have a normal body mass index (range ¼ 20e30 kg/m2), exhibit
no clinically signiﬁcant electrocardiographic abnormalities, have
regular menstrual cycles (with not more than one missed men-
strual period in the past 6 months), and be sexually active. All
subjects were screened for pregnancy and were required to use a
consistent form of contraception during the course of the study.
Breastfeeding subjects were not allowed to participate.
Subjects were excluded if they did not meet all the inclusion
criteria or had any musculoskeletal condition that would not allow
e168 Goldstein et althem to remain in a supine position with their legs spread or in
stirrups for a prolonged time; had a history of alcohol or drug abuse
in the previous year; or had sensitivity to any drugs similar to
alprostadil. Women who previously underwent genital or major
pelvic surgery or trauma, had a vestibule that appeared not to be
healthy in any way, or scored lower than 26.55 on the Female
Sexual Function Index also were excluded.33 Subjects were not
allowed to use any vaginal cream or lubricant within 24 hours of
the thermographic procedure or any prescription medication or
OTC medication that might interfere with study drug evaluation
within 14 or 7 days, respectively, before study drug administration
(Table 1 lists speciﬁcally excluded medications).Subjective Measurements
Each participant was provided with two questionnaires at each
visit: one before dose administration and one after study drug
application (Appendix 1). The predose questionnaire asked
women to rate current genital sensation (eg, warmth in genitals,
genital wetness or lubrication, tingling, or fullness) on a scale from
1 to 5, with 1 representing barely noticeable, 3 representing
neutral, and 5 representing intense. The postdose questionnaire
asked women to report a change, if any, in genital sensation.
Women reporting a noticeable change were asked to rate its in-
tensity on a scale from 1 to 5, with 1 representing barely notice-
able, 3 representing neutral, and 5 representing intense (question
1a). Subjects were asked to describe the sensations on a positive-
negative scale from 1 to 5, with 1 representing negative, 3 repre-
senting neutral, and 5 representing positive (question 1b). These
women also were asked to indicate when the sensation change was
most intense, with the following options: almost immediately after
applying medication; within 5 to 10 minutes after applying
medication; more than 30 minutes after applying medication; or
unable to tell (question 1c). These women were asked to quantify
how long the sensation change lasted: less than 5 minutes; 5 to 10
minutes; longer than 30 minutes; or unable to tell (question 1d).Table 1. Excluded prescription medications
Antidepressant medications
Selective serotonin reuptake inhibitors
Serotonin-norepinephrine reuptake inhibitor antidepressants
Tricyclic antidepressants and monoamine oxidase inhibitors
All anticonvulsant and antiepileptic medications
All antipsychotic medications
Lithium for 6 mo before enrollment




Including cannabis and tetrahydrocannabinol, barbiturates,
heroin, morphine, codeine, oxycodone, hydrocodone
Amphetamines including phentermine
Aromatase inhibitors and tamoxifen
Regular or frequent benzodiazepine use if commenced within past
6 moAdverse Events
All adverse events, whether volunteered by the subject, discov-
ered during general questioning, or detected through physical
examination or other testing, were recorded. Adverse events were
reported as serious or non-serious and expected or unexpected.Data Analysis
The thermographic imaging camera (FLIR system Thermos-
Vision A-Series; FLIR Systems, Inc, N. Billerica, MA, USA) and
validated software from FLIR examinIR and QuickPlot were
used to generate data in the form of genital temperature readings
from thermographic imaging. After positioning the subject
(Figure 1), thermography was started to capture baseline re-
cordings and then allowed to run continuously through 1 hour
after dosing. The subjects were asked to remain still; however, if
they shifted slightly, then the area of interest could be moved
when measuring the temperature on the recording afterward.
Values were recorded continuously, but temperatures were
measured in the three areas of interest every other minute from
5 minutes before dosing until 60 minutes after dosing.
Time to peak response, peak temperature increase from base-
line after study drug application, and area under the curve for
temperature measurements were recorded during this same in-
terval. Comparisons of the time to peak response, peak tempera-
ture increase, and area under the curve between OTC lubricant
and alprostadil topical cream were examined using paired t-test.
Subjective questionnaires were completed at baseline and at
approximately 60 minutes after the dose for each treatment
period. The frequency distributions for responses to postdosing
question 1a and differences between treatments were assessed by
the Mann-Whitney U-test. Responses to other Likert scale-type
items were characterized by frequency distributions only.RESULTS
In all 10 subjects, topical alprostadil cream (Femprox) induced a
statistically signiﬁcant increase in temperature of the vestibule,Figure 1. Arrangement of subject and thermographic camera.
Sex Med 2016;4:e166ee175
Table 2. Change in genital temperature (C) from baseline in over-




























DDAIP-HCl ¼ dodecyl 2-(N,N-dimethyl amino) propionate plus dodecyl-2-
(N,N-dimethyl amino) propionate hydrochloride.
Peripheral Genital Arousal Assessed by Thermography e169clitoris, and vulva compared with the OTC lubricant (Table 2).
Temperature changes were captured with thermographic imaging
(Figure 2). Signiﬁcant differences in genital temperature occurred
at different time points depending on the speciﬁc region (Figure 3).
The most rapid difference in genital temperature between placebo
and alprostadil was seen on the vulva, which demonstrated a sig-
niﬁcant difference at approximately 9 minutes. There was a sig-
niﬁcant difference in temperature seen for the vestibule and clitoris
shortly thereafter, at 11 and 19 minutes, respectively.
Sixty percent of women reported being aware or conscious of
genital sensations with the topical alprostadil cream, but not with
the OTC lubricant, demonstrating concordance between physi-
ologic and subjective assessments (Table 3). Discordance was
noted in 30% who reported being aware or conscious of genital
sensations with the two treatments and 10% who reported not
being aware or conscious of genital sensations with either treat-
ment. No adverse events were reported.DISCUSSION
FSAD is a common problem, affecting millions of women of
all ages. The Prevalence of Female Sexual Problems Associated
with Distress and Determinants of Treatment Seeking study
found that nearly one-fourth of women surveyed endorsed
arousal difﬁculty, with 5% reporting associated distress.10
Prior studies have demonstrated that women with sexual
distress are more likely to have lower overall well-being, higher
negative mood, lower positive mood, more negative feelingsSex Med 2016;4:e166ee175toward their partner, more reports of partners having problems
with sexual performance, and higher depression scores.34,35
The comorbidity between FSAD and HSDD also has been
recognized.33
Despite its prevalence, there have been only a few clinical trials
that have examined pharmaceutical therapies for FSAD in large,
double-blinded, placebo-controlled trials.36,37 There are no
current government-approved topically applied arousal drugs for
FSAD. Use of peripherally acting oral PDE5Is has yielded
inconsistent results. Berman et al38 found a signiﬁcant
improvement in arousal sensation, lubrication, and orgasm in
women who received sildenaﬁl vs placebo, whereas a large
randomized double-blinded study of subjects with FSAD found
no signiﬁcant physical response seen in patients given the active
drug PDE5I.39 Daily tadalaﬁl studied in a small group of pre-
menopausal women with type 1 diabetes with arousal difﬁculty
showed subjective sexual improvement vs placebo.40 Vardenaﬁl
and systemic testosterone caused an improvement in genital
response, as measured by vaginal photoplethysmography, in
women with arousal dysfunction and/or HSDD.41
PDE5Is are taken orally and are associated with bothersome
and unwanted systemic side effects that act to discourage treat-
ment continuation. The most commonly reported adverse events
include headache, ﬂushing, nausea, rhinitis, and visual distur-
bances.42 On-demand subcutaneously delivered bremelanotide, a
centrally acting melanocortin receptor agonist, was used in the
treatment of women with FSAD and HSDD and demonstrated
signiﬁcantly greater improvement in intercourse satisfaction than
placebo.43 This agent has reported side effects of nausea, ﬂush-
ing, somnolence, and increases in blood pressure.
The use of topical vasodilator products for FSAD, such as
alprostadil, are not systemically delivered and thus might be not
be associated with the bothersome, unwanted systemic side ef-
fects of systemically administered vasodilator treatment. In prior
clinical trials examining the safety of alprostadil in women with
FSAD, adverse events were primarily classiﬁed as mild and were
usually transient.23,25 These included local, topical reactions,
such as vaginal itching and burning, and might have been related
to the delivery base compound and not the active drug. Another
advantage of topical products is quick absorption within the
genital tissues, yielding fast onset of effect.
The present study examined the local genital physiologic effect
of topically applied alprostadil to the clitoris and periurethral
tissue in healthy women without visual stimulation. A statistically
signiﬁcant increase in temperature, a marker of increased blood
ﬂow, was recorded in genital tissues. We measured objective
changes in temperature, using FLIR thermography, as a marker of
blood ﬂow in addition to recording subjective change in arousal.
To our knowledge, this is the ﬁrst study to measure local pe-
ripheral genital arousal objectively by measuring temperature
change in women not subjected to visual sexual stimulation.
In three different genital regions—the vulva, vestibule, and
clitoris—there was a signiﬁcant difference in temperature between
Figure 2. Thermography of subjects using over-the-counter lubricant vs alprostadil (dodecyl 2-[N,N-dimethyl amino] propionate plus
dodecyl-2-[N,N-dimethyl amino] propionate hydrochloride) cream.
Sex Med 2016;4:e166ee175
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Figure 3. Mean temperature change from baseline for the
(A) vestibule, (B) clitoris, and (C) vulva using PBO vs FEM. FEM ¼
alprostadil (dodecyl 2-[N,N-dimethyl amino] propionate plus
dodecyl-2-[N,N-dimethyl amino] propionate hydrochloride) cream;
PBO ¼ placebo.
















Predose genital sensation 3.0 2.6 1.9 2.3
Vestibule
Baseline temperature 35.4 34.6 34.4 34.9
Mean change over
61 min
0.44 0.58 1.05 1.00
Maximum temperature
over 61 min
36.5 36.3 33.9 34.3
Time (min) of maximum
temperature
43 48 33 34
Clitoris
Baseline temperature 35.1 34.5 34.1 34.5
Mean change over
61 min
0.30 0.53 0.86 0.83
Maximum temperature
over 61 min
36.2 36.2 33.8 34.0
Time (min) of
maximum temperature
43 49 32 32
Vulva
Baseline temperature 34.6 34.2 33.9 34.2
Mean change over
61 min
0.31 0.26 0.91 0.71
Maximum temperature
over 61 min
35.6 35.1 33.5 33.7
Time (min) of maximum
temperature
61 48 14 22
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time points, with the most rapid difference occurring in the vulva.
Furthermore, increases in genital temperature and arousal
occurred with no reported systemic or local adverse events.
In previous studies using topical alprostadil, Becher et al26
used duplex Doppler ultrasound as the objective measurement
of arousal. They showed that topical application of alprostadil to
the clitoris resulted in a doubling of the peak systolic velocity of
the clitoral artery. These physiologic engorgement changes were
associated with a reported pleasurable sensation of warmth. In
contrast to duplex Doppler ultrasonography, thermography
measurements do not require a human operator in the room
performing “genital arousal” assessments. Thus, thermography
has the ability to record “peripheral genital arousal” in on-goingSex Med 2016;4:e166ee175fashion throughout the study. The use of duplex Doppler ul-
trasound does require placement of the measuring device on the
genitals and interruption of the overall arousal condition of the
subject. Moreover, genital arousal measurements with duplex
Doppler ultrasound are taken only at the time of intervention.
The strong beneﬁts of thermography are that it is non-invasive
and non-obtrusive to study subjects. Privacy of the subject is
maintained and genital arousal is obtained continuously
throughout a study.
There are some limitations to this study. First, unrecognized
psychological and other non-physiologic factors might have
inﬂuenced results in the treatment groups. We did try to mini-
mize this effect by including only healthy subjects without sexual
dysfunction and excluding those currently using antidepressants
or other psychotropic drugs and b-blockers and other medications
known to inﬂuence blood ﬂow and/or arousal. Second, manual
application of the active drug and OTC lubricant might have
inadvertently contributed to genital arousal and biased our results.
However, one would expect to see a similar signiﬁcant increase in
genital temperature in the placebo group, if this were the case,
which was not identiﬁed in the present study. Third, the sample
was small because this was merely a proof-of-principle study.
e172 Goldstein et alThere remain several strengths to our work. This is the ﬁrst study
to use an objective, easily reproducible method such as thermog-
raphy to measure changes in peripheral genital arousal without
visual sexual stimulation. Previous studies investigating the efﬁcacy
of alprostadil in treating arousal dysfunction have relied only on
questionnaires and/or diary logs, which are subject to response bias
and error, or technically difﬁcult measuring tools such as photo-
plethysmography.23e25 Furthermore, our data highlight the po-
tential discordance that can exist between objective arousal and
subjective experience and demonstrate that harmony between the
two is likely necessary for a satisfactory sexual event to occur.
Previous work has highlighted the importance of cerebral
activation in sexual arousal.44 Liao et al24 found that alprostadil
affects patterns of cerebral activation at functional magnetic
resonance imaging and postulated that, when applied to the
genitals, the drug might act not only on local vascular dilation
but also on local chemoreceptors, which could facilitate sexually
related nerve reﬂexes. They offered this theory as a possible
explanation for why topical alprostadil successfully increased
subjective reports of sexual satisfaction, whereas other vasoactive
drugs such as sildenaﬁl did not. Future research on women with
FSAD should investigate the association between central and
subjective arousal and peripheral arousal so that more, successful
therapeutic options, pharmaceutical and non-pharmaceutical,
can be developed to treat this condition.CONCLUSIONS
In summary, topical alprostadil cream (Femprox) adminis-
tered to healthy premenopausal women without visual sexual
stimulation induced statistically signiﬁcant, sustained increases
in genital temperatures of the vestibule, clitoris, and vulva
within 20 minutes compared with the OTC lubricant. Local
arousal pharmacologic therapies for FSAD approved by the U.S.
Food and Drug Administration are currently lacking and
necessitate further inquiry, but this proof-of-principle study
highlights the safety and efﬁcacy of topical alprostadil, just one
of many potential therapeutic options. Treatment of arousal
dysfunction can be challenging and multifactorial. Successful
management of FSAD, and FSD in general, needs to be
approached from a biopsychosocial perspective to address
organic and psychological components of sexual dysfunction.
It remains unclear whether improving peripheral arousal will
result in satisfactory sexual experiences if central arousal is in
disagreement. Future studies are needed to investigate this
relation and to collect objective data on women with diagnosed,
distressing arousal dysfunction.Corresponding Author: Sue W. Goldstein, BA, CCRC, IF,
San Diego Sexual Medicine, 5555 Reservoir Drive, Suite 300,
San Diego, CA 92120, USA. Tel: 619-265-8865; Fax: 619-265-
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APPENDIX 1. SUBJECTIVE QUESTIONNAIRES
Predose
Initials: Number: Date:
Using the scale below, please rate your current genital sensations (eg, warmth in genitals, genital wetness or lubrication, tingling, or
fullness).
1 2 3 4 5
Barely noticeable Neutral Intense
Postdose
Initials: Number: Date:
1. Did you notice any change in genital sensations (eg, warmth in genital, genital tingling or fullness) after applying the study medication?
☐ Yes ☐ No
a. If yes, how intense were those sensations (please circle the number)?
1 2 3 4 5
Barely noticeable Neutral Intense
b. If yes, how would you describe those sensations (please circle the number)?
1 2 3 4 5
Negative Neutral Positive
c. If yes, when were the sensations the most intense (please circle the number)?
1. Almost immediately after applying the medication
2. Within 5e10 minutes after applying the medication
3. More than 30 minutes after applying the medication
4. I couldn’t tell
d. If yes, how long did the sensations last (please circle the number)?
1. Less than 5 minutes
2. Within 5e10 minutes
3. Longer than 30 minutes
4. I couldn’t tell
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